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Abstract
Aberrant zinc (Zn) homeostasis is associated with abnormal control of mammalian growth, although the molecular
mechanisms of Zn’s roles in regulating systemic growth remain to be clarified. Here we report that the cell membrane-
localized Zn transporter SLC39A14 controls G-protein coupled receptor (GPCR)-mediated signaling. Mice lacking Slc39a14
(Slc39a14-KO mice) exhibit growth retardation and impaired gluconeogenesis, which are attributable to disrupted GPCR
signaling in the growth plate, pituitary gland, and liver. The decreased signaling is a consequence of the reduced basal level
of cyclic adenosine monophosphate (cAMP) caused by increased phosphodiesterase (PDE) activity in Slc39a14-KO cells. We
conclude that SLC39A14 facilitates GPCR-mediated cAMP-CREB signaling by suppressing the basal PDE activity, and that this
is one mechanism for Zn’s involvement in systemic growth processes. Our data highlight SLC39A14 as an important novel
player in GPCR-mediated signaling. In addition, the Slc39a14-KO mice may be useful for studying the GPCR-associated
regulation of mammalian systemic growth.
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Introduction
Zn is an essential trace element that is involved in diverse
cellular events by affecting the structural and catalytic functions of
enzymes and transcription factors [1,2]. Zn homeostasis is tightly
controlled by two types of Zn transporters, SLC39/ZIP importers
and SLC30/ZnT exporters [3,4], and by metallothioneins (MTs)
[5], all of which participate in various physiological events. For
instance, SLC39A4/ZIP4 is expressed in the intestine and has a
role in Zn uptake through enterocytes [6,7]. Patients with
Acrodermatitis Enteropathica (AE), who suffer from severe skin
disease and frequent infections, have unusually low serum
concentrations of Zn due to pathogenic loss-of-function mutations
in SLC39A4 [6,7]. Another Zn transporter, SLC39A13/ZIP13, is
expressed on the Golgi and controls the intracellular Zn
distribution in cells of mesenchymal origin. Slc39a13-KO mice
show dwarfism and abnormal bone and cutaneous development,
and a loss-of-function mutation in this gene was found in patients
with a novel type of Ehlers-Danlos Syndrome (EDS), demonstrat-
ing that SLC39A13 plays a critical role in growth control and
connective tissue formation in mouse and human [8]. In fact,
considerable evidence indicates that Zn transporters are involved
in regulating a variety of intracellular signaling pathways in
animals, from flies to vertebrates [8,9,10,11,12,13]. In addition,
Zn is reported to act as a neurotransmitter [14] or rather, as an
allosteric regulator for a Zn-sensing receptor [15], and as an
intracellular signaling molecule [11,16,17].
Somatic growth, which affects body size, is regulated by
endogenous and systemic factors, such as nutrients, hormones,
and growth factors [18,19]. The production of growth hormone
(GH) in the pituitary gland and of insulin-like growth factor (IGF-
I) in the liver are the main endocrine influences on somatic growth
[20]. GH and IGF-I regulate longitudinal bone growth by
controlling endochondral ossification, a defined sequence of events
underlying chondrocyte differentiation in the growth plate
[18,21,22].
Aberrant Zn homeostasis is associated with vertebrate growth
retardation [1,8,20] and metabolic disorders [4,23]. In particular,
Zn deficiency causes dwarfism with reductions in the circulating
GH and IGF-I concentrations [20], and decreased growth-plate
width, which is correlated with reduced cellular Zn content [24].
Intriguingly, the growth retardation cannot be reversed by
maintaining circulating levels of GH or IGF-I through exogenous
administration in Zn-deficient animals [20]. These findings
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intracellular Zn accumulation affect the hormone signaling
cascade(s) required for GH production and chondrocyte differen-
tiation. Since the endocrine system consists of a complex group of
glands involved in growth and metabolism, its perturbation can
broadly affect human health, and it is important to elucidate the
mechanisms underlying the early stages of endocrine disorders.
However, the molecules responsible for Zn homeostasis have been
elusive, and how Zn affects the intracellular signaling that
regulates growth-related endocrine processes has been little
studied.
SLC39A14, a SLC39/ZIP family member, transports the Zn
ion into cells in an in vitro culture system [25,26], but its
physiological roles are still speculative. Here, we show that
SLC39A14 plays important roles in mammalian growth and
energy metabolism by regulating GPCR-cAMP-CREB signaling.
Our findings unexpectedly revealed the biological contribution of
a Zn transporter to GPCR-mediated signaling, which may help to
explain why Zn deficiency results in growth inhibition and
metabolic and endocrine-related disorders.
Results
Slc39a14-KO mice show dwarfism and shortened long
bones
Since Zn-deficient animals with growth retardation show
reduced amounts of cellular Zn [20], it has been assumed that
Zn uptake and its subsequent intracellular accumulation in
pituitary cells and chondrocytes, which are respectively important
for GH production [27] and bone elongation [21], might be a
common, critical initial step required for growth regulation.
Therefore, first, to identify SLC39 members that might contribute
to the influx of Zn into pituitary cells and chondrocytes, we
examined the mRNA expression levels of SLC39 Zn transporters
in these cells. Among the SLC39 family members, SLC39A14 was
expressed in both types of cells (Figure S1). In addition, Slc39a7
was abundant, and Slc39a1, 6, and 13 showed relatively high
expression levels in both cell types. SLC39A7 and SLC39A13 are
present mainly in intracellular organelles [8,28,29], and SLC39A1
and SLC39A6 are localized to both the plasma membrane and
intracellular organelles [30,31,32,33]. Slc39a1-deficient mice are
reported to display no obvious phenotypes under normal growth
conditions [34]. Slc39a8 and Slc39a10 were highly expressed in
chondrocytes but poorly in pituitary cells. Since SLC39A14 is so
far reported to be a SLC39 member that resides only on the
plasma membrane [25,26,35], we chose to examine SLC39A14
further as a candidate regulator of systemic growth via Zn influx.
To investigate the physiological role of SLC39A14 in growth,
we generated mice with a deletion in the Slc39a14 gene. We
constructed a targeting vector designed to eliminate the genomic
region encompassing exons 5–8, which contain the histidine-rich
domain and conserved HEXPHEXGD motif that is common to
SLC39 family members [36], and to delete both alternative splice
variants of SLC39A14, designated SLC39A14A and SLC39A14B,
encoded by exons 4a and 4b, respectively [35] (Figure 1A). After
electroporation of this vector into embryonic stem (ES) cells, the
correctly targeted ES cell clones were identified by southern
blotting analysis (Data not shown). Homologous recombinant
ES cell clones were used to generate Slc39a14-KO heterozygotes,
which were intercrossed to yield Slc39a14-KO homozygotes.
Southern blotting analysis of the genomic DNA of wild-type (WT),
heterozygous (HE), and homozygous (HO) mice confirmed the
deletion of Slc39a14 in the Slc39a14-KO mice (Figure 1B). The
gene knockout was further confirmed by the lack of its mRNA
(Figure 1B). SLC39A14 protein is posttranslationally modified
[25,26]. Western blotting analysis with anti-mouse SLC39A14 and
anti-V5 antibodies demonstrated that a group of high-molecular-
mass bands (compatible with glycosylated oligomers; .89 kDa) of
endogenous SLC39A14 were abundant in the cell lysates of both
wild-type liver and Slc39a14a-v5-overexpressing 293T cells,
whereas these bands were completely absent from lysates of
Slc39a14-KO liver (Figure 1C). These data suggested that
SLC39A14 was successfully deleted in the Slc39a14-KO cells.
The Slc39a14-KO mice exhibited growth retardation compared
to control mice, and dwarfism was visible even in neonates
(Figure 2A). The mice also exhibited torticollis (wry neck,
Figure 2B, upper) and slightly radiolucent bones (Figure 2B,
lower). Bone histomorphometric analysis showed that these
moderate osteoporotic phenotypes were associated with decreased
bone volume and trabecular number, and increased trabecular
separation (Figure 2C). The length of the long bones in the
Slc39a14-KO mice was also significantly reduced (Figure 2D),
indicating that SLC39A14 may play critical roles in skeletal
formation.
Abnormal chondrocyte differentiation in the growth
plate of Slc39a14-KO mice
To investigate the role of SLC39A14 in bone, we first examined
the expression profile of Slc39a14 mRNA by in situ hybridization
analysis. We found relatively high Slc39a14 mRNA expression in
bone tissues such as the limb, spine, and thorax of the E16.5
embryo (Figure 3A), leading us to examine the bone morphology
of the Slc39a14-KO mice.
Endochondral ossification is a process required for the proper
development of long bones and vertebrate growth [37]. In this
process, resting chondrocytes differentiate into proliferative
chondrocytes with a columnar morphology, stop dividing, and
mature into prehypertrophic and then hypertrophic chondrocytes.
We first asked whether the shorter long bones of the Slc39a14-KO
mice resulted from a defect in this process. In the control growth
plate, Slc39a14 was expressed from the resting zone (RZ) to the
prehypertrophic zone (pHZ), with relatively high abundance in the
proliferative zone (PZ) and little in the hypertrophic zone (HZ)
(Figure 3B and C, top panels). The type II Collagen (Col2a1)
gene is exclusively expressed in the RZ and PZ in the growth plate,
and its expression level was increased in the growth plate of the
Slc39a14-KO mice compared to control mice (Figure 3B, lower
panels). In addition, the expression of pHZ markers indian hedgehog
(Ihh) and parathyroid hormone 1 receptor (Pth1r), were enhanced in the
Slc39a14-KO growth plate (Figure 3C, middle panels and
Figure S2), and type X Collagen (Col10a1), an HZ marker, was also
upregulated in the growth plate and in cultured chondrocytes from
the Slc39a14-KO mice (Figure 3C bottom panels, and
Figure 3D). In line with these observations, both the pHZ and
HZ were elongated, and the RZ and PZ were narrowed,
indicating that hypertrophy was accelerated in the Slc39a14-KO
growth plate (Figure 3E).
SLC39A14 positively regulates PTH1R-cAMP-CREB
signaling in chondrocytes
A number of signaling pathways regulate the steps of
chondrocyte differentiation in the growth plate [18,21]. Among
them, we were particularly interested in PTH1R signaling,
because it regulates chondrocyte differentiation by suppressing
hypertrophy in the growth plate [37], and the morphology of the
Slc39a14-KO growth plate partly phenocopies that of PTH1R-
mutant or -deficient mice [38,39]. Parathyroid hormone-related
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PLoS ONE | www.plosone.org 2 March 2011 | Volume 6 | Issue 3 | e18059Figure 1. Generation of Slc39a14-KO mice. (A) Schematic diagram of the construct used to generate Slc39a14-KO mice. The Slc39a14 genomic
structure shows the alternatively spliced exon 4. Exon 4a encodes SLC39A14A, and exon 4b encodes SLC39A14B. (B and C) Homologous
recombination by crossing heterozygotes was confirmed by southern blotting analysis (B, left) using genomic DNA from the tail, RT-PCR (B, right)
using the liver mRNA, and western blotting analysis using liver whole-cell lysate (C, left), from litter mates. Cell lysates from wild-type, Slc39a14-KO
liver (C, left), or Slc39a14a-v5 293T cells (C, right) were treated with or without PNGase F, and then subjected to SDS-PAGE and immunoblotting with
antibodies to SLC39A14 or V5. The oligomeric bands are indicated. Non-specific bands.
doi:10.1371/journal.pone.0018059.g001
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PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e18059Figure 2. Dwarfism, torticollis, scoliosis, osteopenia, and shortened long bones in Slc39a14-KO mice. (A) Left. Appearance of control
(Ctrl) and Slc39a14-KO mice (4-weeks-old). Bar indicates 5 cm. Right. Body weights of 4-week-old control (Ctrl) (male, n=9; female, n=9), Slc39a14-
KO (male, n=10; female, n=7), and neonatal (control, n=22; Slc39a14-KO, n=14) mice. Data represent the mean 6 S.D. (**P,0.01, ***P,0.001). (B)
Frontal views (4-week-old) and X-ray radiographs (8-week-old) of a control (Ctrl) and a Slc39a14-KO female mouse. (C) Bone histomorphometric
analysis of 4-week-old control (Ctrl) and Slc39a14-KO female mice (n=5). Data represent the mean 6 S.D. (*P,0.05). (D) X-ray radiographs of the
femurs (8-week-old), and the tibial length (6-week-old) of control (Ctrl) and Slc39a14-KO mice (n=5). Data represent the mean 6 S.D. (***P,0.001).
doi:10.1371/journal.pone.0018059.g002
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PLoS ONE | www.plosone.org 4 March 2011 | Volume 6 | Issue 3 | e18059Figure 3. Abnormal chondrocyte differentiation in the growth plate of Slc39a14-KO mice. (A) In situ hybridization analysis for Slc39a14 in
an embryo at 16.5 dpc, and magnified images of the limb (1), spine (2), and thorax (3). Green arrowheads indicate Slc39a14 expression. (B and C) In
situ hybridization analysis for Slc39a14, Col2a1, Ihh, and Col10a1 in the growth plates from 4-week-old control (Ctrl) and Slc39a14-KO mice. (D)
Col10a1 levels in control (Ctrl) and Slc39a14-KO chondrocytes. Data represent the mean 6 S.D. (**P,0.01). (E) H&E staining of the growth plates from
control (Ctrl) and Slc39a14-KO mice (4-week-old).
doi:10.1371/journal.pone.0018059.g003
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response element-binding protein (CREB) by the nuclear-translo-
cated catalytic alpha subunit of protein kinase A (PKA-Ca), and
the phosphorylated CREB (p-CREB) then induces the transcrip-
tion of c-fos [40]. As shown in Figure 4A, the PTHrP-mediated c-
fos transcription was significantly reduced in the Slc39a14-KO
chondrocytes. The induction of CREB phosphorylation and the
nuclear translocation of PKA-Ca in response to PTHrP treatment
were also downregulated in the Slc39a14-KO cells (Figure 4B),
although the PTH1R expression level was not diminished in these
cells (Figure 4B and Figure S2).
PTHrP stimulation leads to elevated cAMP levels through
adenylyl cyclase (AC) activation, and cAMP then activates PKA by
binding to its regulatory subunit [41]. In the Slc39a14-KO
chondrocytes, the basal cAMP level was significantly reduced
(Figure 4C, left), and even after treatment with either PTHrP or
the AC activator forskolin (FSK), the level was lower than in
control chondrocytes, although the fold increase in cAMP levels
after stimulation was comparable between the control and
Slc39a14-KO chondrocytes (Figure 4C, right). These findings
indicated that SLC39A14 was not required for the ligand-
mediated AC activation, but rather, for maintaining the basal
cAMP level in chondrocytes. Since PDE is known to control the
cAMP level through its enzymatic activity [42], we next asked
whether PDE activity was elevated in the Slc39a14-KO chondro-
cytes. As shown in Figure 4D, the Slc39a14-KO chondrocytes
showed enhanced PDE activity and a reduced cAMP level
compared with control cells, both of which were brought to
normal levels by treatment with a PDE inhibitor, 3-isobutyl-1-
methylxanthine (IBMX), suggesting that SLC39A14 negatively
regulates PDE activity to upregulate the PTH1R-signaling
pathway.
SLC39A14 was localized to the plasma membrane (Figure 5A),
and is thought to increase the intracellular Zn level by Zn influx
[25,26], raising the possibility that SLC39A14-mediated Zn influx
plays a role in chondrocyte differentiation. To address this
hypothesis, we measured the Zn level in control and Slc39a14-
KO growth plates. Electron Probe X-ray Micro Analysis (EPMA)
revealed that the intracellular Zn level was significantly decreased
in the PZ of the Slc39a14-KO growth plate (Figure 5B),
consistent with the idea that SLC39A14 functions to transport
Zn from the outside to the inside of a cell. The forced introduction
of Zn into cells using Zn plus pyrithione elevated the cAMP levels
in Slc39a14-KO chondrocytes (Figure 5C, left) with a significant
reduction of the PDE activity (Figure 5C, right) in a Zn-
concentration- and time-dependent manner. Furthermore, the
ectopic expression of SLC39A14 in Slc39a14-KO cells rescued the
intracellular Zn (Figure 5D, left), and cAMP levels (Figure 5D,
right).
The mRNA expression levels of other SLC39 members, which
reside on the cell surface or in intracellular spaces, such as Slc39a1,
6,7 ,8, 10, and 13, were not significantly altered in the Slc39a14-
KO chondrocytes (Figure S3). Taken together, these results were
consistent with the idea that SLC39A14 on the plasma membrane
helps to maintain the steady-state level of PTH1R-mediated
signaling by importing Zn to inhibit PDE activity, and strongly
suggest that SLC39A14 plays a unique role in GPCR signaling in
these cells, with little backup by the upregulation of other SLC39
family members to compensate for its loss of function.
SLC39A14 positively regulates GH production via GHRHR
signaling in the pituitary gland
Given that SLC39A14 negatively regulates PDE activity and
that PDEs regulate several GPCR signaling pathways [42], we
looked for likely GPCR pathways that might be affected by
SLC39A14 expression. Since the Slc39a14-KO mice showed
dwarfism, which is also seen in GH-deficient mouse models and
humans [19], we investigated the role of SLC39A14 in signaling
through growth hormone releasing hormone (GHRH) receptor
(GHRHR), a GPCR expressed on pituitary somatotroph cells that
induces the production and secretion of GH upon stimulation
[27,43]. We found that the levels of both pituitary cAMP and Zn
were significantly lower in the Slc39a14-KO mice compared with
control mice (Figure 6A). Furthermore, an intravenous bolus
injection of GHRH elicited a smaller increase in the plasma GH
level in the Slc39a14-KO mice than in control mice (Figure 6B).
In addition, the induction of Gh during fasting, to which GHRH-
mediated secretion contributes [44], was defective in the Slc39a14-
KO mice (Figure 6C).
Notably, the Slc39a14-KO mice also showed a reduction in
serum IGF-I (Figure 6D) and hepatic Igf-I expression levels
(Figure 6E), which was not due to diminished growth hormone
receptor (Ghr) expression, but could be explained by the impaired
GH production (Figure 6E), because GH secretion stimulates
IGF-I synthesis [45]. As seen in the chondrocytes, the mRNA
expression levels of other SLC39 members were not significantly
altered in the Slc39a14-KO pituitary cells (Figure S3). Collec-
tively, these results indicated that SLC39A14 is selectively involved
in the signaling through GHRHR, a GPCR in the pituitary gland.
SLC39A14 positively regulates gluconeogenesis via GCGR
signaling in the liver
Since SLC39A14 is expressed in the liver (Figure. 1B) [25,35],
it may control gluconeogenesis, which occurs predominantly in the
liver via signaling through the glucagon receptor (GCGR), a
GPCR. Induction of the phosphoenolpyruvate carboxykinase (Pepck) gene
in the liver is a critical event in the gluconeogenesis mediated by
GCGR signaling [46]. As shown in Figure 7A, fasting-induced
Pepck expression was significantly reduced in the Slc39a14-KO
mice, although the Gcgr expression level did not change. In line
with the lower Pepck induction, 36 hours of fasting significantly and
continuously reduced the plasma glucose level in the Slc39a14-KO
mice, whereas the plasma glucose level in the control mice
plateaued after 18 hours (Figure 7B). These data indicated that
fasting gluconeogenesis was significantly impaired in the Slc39a14-
KO mice.
The Slc39a14-KO liver had a lower cAMP level, a higher PDE
activity (Figure 7C), and a lower Zn level (Figure 7D, left) than
the control liver. The reduced Zn level was confirmed by the
reduction of the mRNA expression of Mt-I, a Zn indicator whose
expression is induced by Zn via the metal response element (MRE)
[47] (Figure 7E), whereas the level of iron (Fe) in the liver was not
affected in the Slc39a14-KO mice (Figure 7D). Taken together,
these data indicated that SLC39A14 positively controls gluconeo-
genesis through GCGR, and thus facilitates the hepatic cAMP-
CREB signaling pathway.
Discussion
Our current study demonstrated that a Zn transporter,
SLC39A14, controls GPCR-mediated signaling by maintaining
the basal cAMP level and suppressing PDE activity. Our results
showed that SLC39A14 is a novel endogenous regulator for
systemic growth and energy homeostasis, and its role may provide
a mechanism for the Zn-mediated regulation of endocrine
signaling (Figure 8).
PTHrP-PTH1R signaling plays an important role in the
endochondral ossification process, in which it blocks the
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PLoS ONE | www.plosone.org 6 March 2011 | Volume 6 | Issue 3 | e18059Figure 4. SLC39A14 positively regulates PTH1R-cAMP-CREB signaling in chondrocytes. (A) PTHrP-induced c-fos levels in control (Ctrl) and
Slc39a14-KO chondrocytes. Data represent the mean 6 S.D. (***P,0.001). (B) CREB phosphorylation and nuclear PKA-Ca translocation in control (Ctrl)
and Slc39a14-KO chondrocytes with PTHrP treatment. Whole-cell lysate (upper panels) or the nuclear fraction (lower panels) was subjected to SDS-
PAGE and immunoblotting with antibodies to the indicated proteins. (C) cAMP level and the fold-increase in cAMP level in control (Ctrl) and Slc39a14-
KO chondrocytes before and after PTHrP or FSK treatment. Data represent the mean 6 S.D. (**P,0.01; ***P,0.001; N.S., no significance). (D) Effect of
IBMX treatment on the PDE activity and cAMP level in control (Ctrl) and Slc39a14-KO chondrocytes. Data represent the mean 6 S.D. (*P,0.05,
***P,0.001).
doi:10.1371/journal.pone.0018059.g004
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PLoS ONE | www.plosone.org 7 March 2011 | Volume 6 | Issue 3 | e18059Figure 5. Zn positively regulates the cAMP level and facilitates PTH1R signaling. (A) Localization of SLC39A14 in transfected primary
chondrocytes. SLC39A14 was labeled with anti-V5 (green), nuclei with DAPI (blue), and actin with phalloidin (red). (B) Electron probe X-ray
microanalysis (EPMA) in the PZ and HZ of the growth plates from control (Ctrl) and Slc39a14-KO mice. The Zn levels in 10 cells in each zone were
measured. Data represent the mean 6 S.D. (***P,0.001). (C) Effect of Zn plus the ionophore pyrithione on the cAMP level and the PDE activity in
control (Ctrl) and Slc39a14-KO chondrocytes. The cells were treated with Zn plus pyrithione at the indicated concentrations and time points. Data
represent the mean 6 S.D. (*P,0.05, **P,0.01, ***P,0.001). (D) Intracellular Zn and cAMP levels in control (Ctrl) and Slc39a14-KO chondrocytes after
the transduction of empty (Mock) or Slc39a14 cDNA-carrying lentivirus for 2 days. The intracellular Zn level was measured as the maximal emission at
516 nm (excitation at 494 nm) using a Varioskan after mixing FluoZin-3 with denatured cell lysates. The cAMP levels were measured after PTHrP
treatment for 20 min. Data represent the mean 6 S.D. (n=3 per condition) (*P,0.05, **P,0.01, ***P,0.001).
doi:10.1371/journal.pone.0018059.g005
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cytes [37]. We concluded that SLC39A14 positively regulates
PTHrP-PTH1R signaling based on the following findings. (1) The
morphology of the Slc39a14-KO growth plate featured accelerated
hypertrophy, characterized by the elongated pHZ and HZ, similar
to observations in genetically manipulated-Pth1r mice [38,39]. (2)
Figure 6. SLC39A14 positively regulates GH production via GHRHR signaling in the pituitary gland. (A) cAMP and intracellular Zn levels
in pituitary cells (12-week-old control (Ctrl) and Slc39a14-KO mice (n=3)). M.F.I. represents the mean fluorescent intensity. Data represent the mean 6
S.D. (*P,0.05). (B) Human GHRH (500 mg/kg) was injected intravenously into 8-week-old control (Ctrl) and Slc39a14-KO mice (n=8). Plasma was
collected at the indicated times after injection, and the GH concentration was measured. Data represent the mean 6 S.E.M. (*P,0.05). (C) Gh
induction in the pituitary glands from 36-hours fasted control (Ctrl) and Slc39a14-KO mice (14–17-week-old, n=3). Data represent the mean 6 S.D.
(***P,0.001). (D) Serum IGF-I concentration (3-week-old control (Ctrl), n=9; Slc39a14-KO, n=12). Data represent the mean 6 S.D. (***P,0.001). (E)
Hepatic Igf-I (n=7) and Ghr (n=3) levels in 3-week-old control (Ctrl) and Slc39a14-KO mice. Data represent the mean 6 S.D. (***P,0.001).
doi:10.1371/journal.pone.0018059.g006
SLC39A14 Controls GPCR-Mediated Signaling
PLoS ONE | www.plosone.org 9 March 2011 | Volume 6 | Issue 3 | e18059Figure 7. SLC39A14 positively regulates gluconeogenesis via GCGR signaling in the liver. (A) Hepatic Pepck and Gcgr levels in 18-hours
fed or fasted control (Ctrl) and Slc39a14-KO mice (16-week-old, n=2). Data represent the mean 6 S.D. (***P,0.001). (B) Plasma glucose level in 18–
36-hours fasted control (Ctrl) and Slc39a14-KO mice (7–52-week-old, n=8). Data represent the mean 6 S.E.M. (*P,0.05). (C) cAMP level and PDE
activity in the liver from control (Ctrl) and Slc39a14-KO mice (4–8-week-old, n=3). Data represent the mean 6 S.D. (*P,0.05, **P,0.01). (D) Hepatic
Zn and Fe levels in control (Ctrl) and Slc39a14-KO mice measured by ICP-MS. Data represent the mean 6 S.D. (*P,0.05). (E) Hepatic Mt-I level in
control (Ctrl) and Slc39a14-KO mice (16-week-old, n=2). Data represent the mean 6 S.D. (**P,0.01).
doi:10.1371/journal.pone.0018059.g007
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PLoS ONE | www.plosone.org 10 March 2011 | Volume 6 | Issue 3 | e18059The Slc39a14-KO growth plate showed increased expression levels
of the hypertrophic markers Ihh and Col10a1. PTH1R signaling is
reported to inhibit their expression levels [41,48], consistent with
the observation of elongated pHZ and HZ in the Slc39a14-KO
mice. (3) Slc39a14-KO chondrocytes possessed a lower potential
for PTH1R signal transduction.
The accelerated hypertrophy in Pth1r mutant mice might be
caused not only by the accelerated differentiation of proliferative
cells into hypertrophic cells, but also by the accelerated
differentiation of resting cells into proliferative cells [39]. Given
that Ihh acts to promote the differentiation of resting to
proliferative cells and Ihh-KO mice display markedly reduced
proliferation, with hypertrophy at inappropriate positions [49], it is
reasonable to propose that the enhanced Ihh expression might
stimulate the proliferation of resting chondrocytes accompanied by
an increase in Col2a1 expression (Figure 3B), leading to
narrowing of the RZ and PZ (Figure 3E), in close coordination
with accelerated hypertrophy in the Slc39a14-KO growth plate.
However, the morphological abnormality of the Slc39a14-KO
growth plate was less severe than that of the Pth1r mutant. It is
possible that other Zn transporters and/or Zn-permeable channels
[50] have similar functions (e.g. Zn transport activity) as the
SLC39A14 protein, although their mRNA expression levels were
not altered by the loss of SLC39A14 (Figure S3). This issue
remains to be clarified. Nonetheless, the intracellular Zn level was
significantly reduced in the PZ but not the HZ in the Slc39a14-KO
mice (Figure 5B), reflecting the expression pattern of Slc39a14 in
the growth plate (Figure 3B and 3C). Our results collectively
indicate that SLC39A14 plays an indispensable role in proper
chondrocyte differentiation in the growth plate, by positively
regulating PTH1R-mediated signaling.
Besides PTHrP-PTH1R signaling, the role of the GH-IGF-I
axis in longitudinal bone growth is well established [18,22]. It has
been suggested that GH acts locally at the growth plate to induce
IGF-I production, which then stimulates the proliferation of
chondrocytes in a paracrine/autocrine manner, or induces resting
chondrocytes to enter a proliferative state, independent of
endocrine or paracrine IGF-I [22]. The Slc3914-KO mice showed
significant decreases in their plasma concentrations of GH and
IGF-I (aberrant GH-IGF-I axis), correlating with a low Zn level in
the pituitary gland. In sharp contrast to mice lacking the Ghr gene,
which have a normal birth weight and size [51], the Slc39a14-KO
mice had a reduced birth weight and size (Figure 2A and data
not shown). In addition, the growth plates of Igf-I-deficient mice
display reduced hypertrophy [52], whereas hypertrophy was
augmented in the Slc39a14-KO mice. Therefore, it is unlikely
that the reduced GH and IGF-I levels impair chondrocyte
differentiation in the Slc39a14-KO mice; rather, their role is
probably related to the postnatal systemic growth retardation of
these mice. However, we do not exclude the possibility that the
reduced IGF-I level has an effect on growth during gestation,
because Igf-1-deficient mice show intrauterine growth retardation
Figure 8. Schematic model for the regulation of GPCR-mediated signaling by SLC39A14. SLC39A14 regulates the basal cAMP level by
suppressing PDE activity, through either the direct provision of Zn to PDE or the indirect provision via unidentified molecular chaperone(s) (Protein
X). This system may facilitate the GPCR-cAMP-CREB pathway in endocrine-system reactions.
doi:10.1371/journal.pone.0018059.g008
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clarification. Nonetheless, it seems likely that in systemic growth,
SLC39A14 plays an important role in controlling GH production
by regulating the basal cAMP level in GHRHR-mediated
signaling. This highlights SLC39A149s importance as a positive
GPCR regulator, not only in endochondral ossification, but also in
GH production, thus concomitantly regulating systemic growth
through these processes. Finally, our findings provide a mecha-
nism that explains the reductions in GH and IGF-I in cases of Zn
deficiency [20].
Here, we extended previous work on the importance of
SLC39A14 in the signaling of a hepatic GPCR, GCGR, which
controls gluconeogenesis during fasting. The liver regulates the
metabolism of both Zn and Fe [54,55]. We found that neither the
hepatic (Figure 7D) nor the serum (data not shown) Fe level
was altered in the Slc39a14-KO mice, suggesting that SLC39A14
specifically regulates the Zn metabolism in the liver at steady state.
Overall, our results indicate that SLC39A14 may be a new player
in the positive regulation of GPCR-mediated signaling in various
systems (Figure 8).
It is noteworthy that the single ablation of the Slc39a14 gene was
sufficient to provoke abnormal chondrocyte differentiation. There
are phenotypic similarities between the Slc39a14-KO mice and
mice deficient in SLC39A13, another Zn transporter that is also
required for mammalian growth. Slc39a13-KO mice show
systemic growth retardation accompanied by impaired endochon-
dral ossification [8]. In addition, Slc39a14 and Slc39a13 have
similar distributions in the growth plate; they are both highly
expressed in the PZ. However, the growth plate morphologies of
the Slc39a14-KO mice are quite different from those of the
Slc39a13-KO mice: the PZ shows narrowing in the Slc39a14-KO
mice but elongation and disorganization in the Slc39a13-KO mice,
and the HZ is elongated in the Slc39a14-KO mice, but is scanty in
Slc39a13-KO mice, suggesting that SLC39A14 and SLC39A13
have distinct biological roles in growth control. These Zn
transporters also have different cellular localizations. SLC39A14
is a cell-surface-localized transporter that controls the total cellular
Zn content, whereas SLC39A13 localizes to the Golgi and
regulates the local intracellular Zn distribution. Thus, the
intracellular Zn status (e.g. accumulation and distribution of Zn)
is controlled by various Zn transporters (e.g. SLC39A14 and
SLC39A13), which influence distinct signaling pathways (GPCR
by SLC39A14 and BMP/TGF-b by SLC39A13) leading to
mammalian growth, in which many essential signaling events
participate [18,21,22]. Furthermore, the expression level of
Slc39a13 was not changed in Slc39a14-KO cells (Figure S3),
suggesting that SLC39A14 plays a unique biological role in
controlling the GPCR signaling pathway, with little help from a
backup system to compensate for its loss. The intracellular
localization, expression level, Zn-transport activity, and post-
translational modifications [4] may determine the specificity of
each Zn transporter. Thus, our findings strongly suggest that
SLC39A14 and SLC39A13 control skeletal growth by differen-
tially regulating the Zn status to affect distinct signaling pathway(s),
even though the growth phenotypes of their KO mice are similar.
Our results support a new concept that different ‘‘Zn transporter-
Zn status’’ axes act in unique signaling pathways to promote
systemic growth.
In this study, it was not clarified how Zn acts through
SLC39A14 to suppress PDE activity. SLC39A14 may regulate
PDE activities by modulating the intracellular Zn level [56,57] in
tissues that express SLC39A14 and contain high concentrations of
Zn [20,58,59]. As illustrated in Figure 8, the SLC39A14-
mediated inhibitory effect may be due to the direct action of the
transported Zn or to an indirect one via unidentified molecular
chaperone(s) (Protein X) that receives Zn through SLC39A14 and
provides it to PDE. Since GPCRs are expressed in numerous
tissues, the Slc39a14-KO mice may be useful for studying GPCR-
mediated biological events. Further studies on the mechanism by
which SLC39A14 provides Zn to target molecules should help
illuminate the regulation of GPCR-mediated signaling and Zn–
associated biological events.
Materials and Methods
Mice
Mice were maintained on a 12-hour light-dark cycle, with a
regular unrestricted diet available ad libitum. Mice at 6-8-weeks old
were used for X-ray radiographic bone analysis, using a composite
X-ray analyzing system (In vivo 3D Micro X-ray CT System
R_mCT, Rigaku), and for bone histomorphometric analysis, using
a semiautomatic image analyzing system (OsteoplanII; Carl Zeiss).
Four-week-old mice were used for in situ hybridization analysis by
the method of GENOSTAFF CO., LTD., and for analysis of the
intracellular Zn level using an Electron Probe X-ray Micro
Analyzer (JXA9200 II, JOEL). For analysis of the pituitary gland
and liver, 3-52-week-old mice were evaluated under ad libitum or
fasted conditions.
Generation of Slc39a14-KO mice
The knockout mouse line of the Slc39a14 gene was generated
using previously described methods [60]. The RPCI-23 MM BAC
(bacterial artificial chromosome) clone (Clone ID; 125B6),
containing the mouse Slc39a14 gene, was purchased from
Invitrogen. A targeting vector was created to eliminate the
genomic region encompassing exons 5–8 by inserting a Neo-
cassette between exons 4 and 9 of Slc39a14, and deleting the
intervening exons (Figure. 1A). This region contains the histidine-
rich domain and conserved HEXPHEXGD motif that are
common to SLC39 family members [36]. This vector was
introduced into B66129+Ter/SvJcl hybrid M1 ES cells, the
cloned homologous recombinants were selected with antibiotics,
and the genotypes were verified. We developed chimeric mice with
the targeted ES-cell clones, and obtained homozygous mice by
interbreeding the offspring. Heterozygous mice were phenotypi-
cally normal, and crosses between heterozygotes produced
homozygous mutant mice according to Mendelian expectations.
Genotyping was done by PCR using Taq polymerase (GE
Healthcare). The primers used for genotyping were:
Forward: 59- TGCTGCTGCTATTTGGGTCT -39 for the
wild-type allele
Forward: 59- CTCGTGCTTTACGGTATCGC -39 for the
targeted allele and Reverse: 59-GAATGCTGCATTGAAAA-
GGTC –39, which was the same for the wild-type and targeted
alleles.
Ethics Statement
All animal experimental procedures were conducted according
to guidelines approved by the RIKEN Institutional Animal Care
and Use Committee (#22-013).
Plasmid construction, transfection, and viral infection
The coding regions of the mouse Slc39a14a and Slc39a14b genes
[35] were isolated from a liver cDNA library of the C57BL/6
mouse. To construct a C-terminally V5-tagged Slc39a14a
(Slc39a14a–v5), the Slc39a14a fragments were amplified by PCR,
followed by sequencing and cloning into the expression vector
pcDNA6.2/V5-DEST (Invitrogen). To construct an N-terminally
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ral vector, the HA-tag sequence was inserted into the N-terminus
of Slc39a14a or Slc39a14b by PCR, followed by ligating with CSII-
CMV-IRES-hrGFP. Cells were transfected with expression
vectors using Lipofectamine 2000 (Invitrogen). For lentiviral
infections, 293T cells were transfected with Slc39a14a or Slc39a14b
cDNA-containing CSII-CMV-IRES-hrGFP, pMDLg/p.RRE,
pRSV-Rev, and pMD.G (VSV-G). After a 12-hour incubation,
the culture medium was replaced with fresh medium, and then
collected 24- and 48-hours later. The culture supernatants
containing packaged lentivirus were pooled and concentrated
using a Lenti-X concentrator (Clontech). The virus pellet was
resuspended, and the virus titer was measured using the Lenti-X
qRT-PCR Titration Kit (Clontech). Two or three days after
starting the primary chondrocyte cell culture, the cells were
infected with the Slc39a14a or Slc39a14b cDNA-carrying lentivirus
in 8 mg/ml polybrene (Sigma) containing 10% FCS-a-MEM.
After 2 days of infection, the cells were used for further analysis.
Reagents and Antibodies
Human PTHrP (1-34) and (Nle
27)-GHRH (1-29) amide were
from Bachem. FSK and the broad-range PDE inhibitor (IBMX)
were from Sigma. Pyrithione and Zn sulfate heptahydrate were
from Molecular Probes and Wako Pure Chemical Industries, Ltd.,
respectively. Peptide N-glycosidase F (PNGase F) was from New
England Biolabs. The anti-mouse SLC39A14 antibody was raised
by immunizing rabbits with a KLH-conjugated peptide
(CNSELDGKAPGTDEKV). Anti-CREB and anti-p-CREB
(S133; 634-2) antibodies were from Millipore. The anti-PKA-Ca
antibody was from Cell Signaling Technology. The anti-tubulin
and anti-HDAC1 antibodies were from Sigma. The anti-PTH1R
(K-20) and anti-V5 antibodies were from Abcam and Invitrogen,
respectively.
PNGase F treatment
Cell lysates were denatured in denaturing buffer (0.5% SDS and
40 mM DTT) at 37uC for 30 min. Nonidet P-40 and sodium
phosphate (pH 7.5, 25uC) were added at final concentrations of
1% and 50 mM, respectively. Subsequently, PNGase F was added
and the mixture was incubated at 37uC for 1 h. The samples were
then denatured with SDS-PAGE loading buffer (37uC for 15 min)
prior to immunoblotting.
Measurement of cAMP level and PDE activity
The cAMP level and PDE activity in primary chondrocytes,
pituitary cells, and liver were measured with the cAMP-Glo assay
kit and PDE-Glo Phosphodiesterase assay kit (Promega), according
to the manufacturer’s instructions.
RT-PCR and Quantitative RT-PCR (RT-qPCR) analyses
The total RNA was extracted from primary chondrocytes,
pituitary cells, and liver using Sepasol-RNA I (Nacalai Tesque),
and reverse-transcribed with an oligo-(dT) primer and reverse
transcriptase (ReverTra Ace, Toyobo). RT-qPCR analysis was
performed using the SYBR Green PCR Master Mix (Applied
Biosystems). Samples were normalized to the Gapdh or b-actin
expression. Primer sequences are available upon request.
Enzyme-linked Immunosorbent assay (ELISA)
The serum IGF-I and plasma GH level were measured using
the Mouse/Rat IGF-I Quantikine ELISA Kit (R&D Systems) and
Rat/Mouse Growth Hormone ELISA kit (Millipore), according to
the manufacturers’ instructions.
Measurement of Zn level
To measure the intracellular Zn level in pituitary cells, the
pituitary gland was isolated and incubated with Trypsin/EDTA
(Nacalai Tesque) at 37uC for 10 min. After being washed with PBS,
the cells were loaded with 10 mM cell-permeant FluoZin
TM-3 AM
(Invitrogen) in plain RPMI medium (Sigma) at 37uC for 30 min.
The cells were further incubated in fresh plain RPMI medium for
30 min prior to measuring the Zn level by flow cytometric analysis.
For the experiment using lentivirus-transduced chondrocytes,
the cell lysates were boiled at 98uC for 10 min to inactivate the
reporter protein, hrGFP, expressed from the IRES translation
initiation sequence in the lentiviral vector. The cell lysates were
diluted in cell-impermeant 10 mM FluoZin
TM-3, tetrapotassium
salt (Invitrogen) in 10 mM Tris-HCl (pH 7.4), and incubated for
30 sec prior to measuring the maximal emission at 516 nm
(excitation at 494 nm) using a Varioskan (Thermo Electron
Corporation). The hepatic Zn and Fe levels were measured by
Inductively Coupled Plasma Mass Spectrometry (ICP-MS). An
Electron Probe X-ray Micro Analyzer (JXA9200 II, JOEL) was
used to measure the intracellular Zn level in the growth plate.
Control- and Slc39a14-KO-derived growth plates were fixed with
1.25% glutaraldehyde and 1% paraformaldehyde in 0.1 M
phosphate buffer, pH 7.4, then post-fixed in 2% osmium
tetroxide, dehydrated in an ascending series of alcohol, and
embedded in epoxy resin. The proliferative and hypertrophic
chondrocytes in the embedded growth plate were scanned by an
electron beam. The characteristic X-ray for Zn generated by the
electron-beam exposure was detected.
Histological and in situ hybridization analyses
Paraffin sections (4,6 mm) processed from the tibia of 4-week-
old mice or E17.5 embryos were prepared for hematoxylin and
eosin (H&E) staining and for in situ hybridization analysis.
Digoxigenin-labeled antisense RNA probes for Slc39a14, Col2a1,
Col10a1, Ihh and Pth1r were used for in situ hybridization analysis
by the method of GENOSTAFF CO., LTD. The sections used in
the in situ hybridization analysis were counterstained with
Kernechtrot stain solution. The probe sequences and hybridiza-
tion conditions are available upon request.
Isolation and culture of mouse primary chondrocytes,
subcellular fractionation, immunoblotting, confocal
microscopy, X-ray analysis, and bone histomorphometric
analysis
Primary chondrocytes were isolated from the ribs as described
previously [8]. The subcellular fractionation, immunoblotting,
confocal microscopy, X-ray analysis, and bone histomorphometric
analysis were performed using previously described methods [8].
Statistical analysis
Differences among multiple groups were compared by 1-way
ANOVA followed by a post-hoc comparison using Fisher’s PLSD
test. The two-tailed Student’s t-test was used to analyze the
difference between two groups.
Supporting Information
Figure S1 mRNA expression of Slc39s in pituitary cells
and chondrocytes. The mRNA expression of Slc39s in pituitary
cells and chondrocytes was assessed by RT-PCR. The Gh, Col2a1
and Col10a1 mRNA levels are shown as controls for the pituitary
cells and chondrocytes, respectively.
(TIF)
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growth plate of Slc39a14-KO embryo. In situ hybridization
analysis for Ihh and Pth1r in the growth plates from E17.5 control
(Ctrl) and Slc39a14-KO embryos.
(TIF)
Figure S3 The mRNA expression levels of other Slc39s
in Slc39a14-KO chondrocytes and pituitary cells. (A) The
mRNA expression levels of Slc39s in control (Ctrl) and Slc39a14-
KO chondrocytes. Data represent the mean 6 S.D. (N.S., no
significance). (B) The mRNA expression levels of Slc39s in control
(Ctrl) and Slc39a14-KO pituitary cells. Data represent the mean 6
S.D. (N.S., no significance).
(TIF)
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